How should I manage a patient with triglycerides of 214 mg/dL and HDL cholesterol of 18 mg/dL?

Critical Dyslipidemia Requiring Immediate Aggressive Intervention

This patient has critically low HDL cholesterol (18 mg/dL) combined with elevated triglycerides (214 mg/dL), representing severe atherogenic dyslipidemia that demands immediate intensive lifestyle modification and pharmacotherapy to reduce cardiovascular mortality and morbidity risk.

Immediate Priority Actions

1. Assess Cardiovascular Risk Status

Determine if this patient falls into:

• Secondary prevention (known ASCVD): Highest priority for aggressive treatment
• Primary prevention with diabetes + risk factors: Very high risk
• Primary prevention without diabetes: Risk stratify using 10-year ASCVD calculator

The HDL of 18 mg/dL is critically low (normal threshold is >40 mg/dL for men, >50 mg/dL for women) 1, 2, and triglycerides of 214 mg/dL fall into the 200-499 mg/dL range requiring specific intervention 1, 3.

2. Rule Out Secondary Causes

Before initiating therapy, evaluate for:

• Uncontrolled diabetes (check HbA1c, fasting glucose)
• Hypothyroidism (TSH)
• Kidney disease (creatinine, urinalysis)
• Liver disease (liver function tests)
• Medications causing dyslipidemia (thiazides, beta-blockers, estrogens, corticosteroids)
• Alcohol consumption (critical contributor to both low HDL and high triglycerides)

2

Treatment Algorithm

Step 1: Intensive Lifestyle Modifications (Start Immediately)

Dietary interventions 1, 4:

• Saturated fat <7% of total calories
• Cholesterol <200 mg/day
• Trans fatty acids <1% of total calories
• Eliminate or drastically reduce alcohol (major contributor to both abnormalities)
• Increase omega-3 fatty acids from fish
• Add plant stanols/sterols (2 g/day)
• Increase viscous fiber (>10 g/day)

Physical activity 1, 4:

• 30-60 minutes of moderate-intensity aerobic activity daily (minimum 5 days/week)
• Resistance training 2 days/week

Weight management 1, 4:

• Target BMI 18.5-24.9 kg/m²
• If overweight, aim for 10% body weight reduction in first year

Step 2: Pharmacotherapy (Initiate Concurrently with Lifestyle Changes)

Primary Therapy: High-Intensity Statin

Initiate immediately regardless of LDL-C level 4, 5, 6:

• Statins provide 10-30% triglyceride reduction and modest HDL increase
• Target LDL-C <100 mg/dL (or <70 mg/dL if very high risk)
• Calculate non-HDL-C (total cholesterol minus HDL-C): Target <130 mg/dL since triglycerides are 200-499 mg/dL 1, 3

Secondary Therapy: Address Triglycerides and Non-HDL-C

For triglycerides 200-499 mg/dL with non-HDL-C not at goal 1, 3, 7:

Option 1 (Preferred): Intensify statin therapy first 1, 3

Option 2: Add niacin (after statin optimization) 1, 3, 7

• Can raise HDL-C by 15-35%
• Reduces triglycerides by 20-50%
• Caution: Monitor for glucose elevation, uric acid elevation, liver enzymes
• Prescription niacin required (not dietary supplements)

Option 3: Add fibrate therapy (after statin optimization) 1, 3, 7

• Fenofibrate preferred over gemfibrozil (lower myopathy risk with statins)
• Critical warning: Use low-dose statin with fibrate combination to minimize severe myopathy risk 8, 9
• Monitor creatinine and liver enzymes

Option 4 (Emerging): Consider icosapent ethyl if patient has ASCVD or diabetes plus ≥2 risk factors 5, 10, 11

• Dose: 4 g/day
• Shown to reduce cardiovascular events in patients with triglycerides ≥150 mg/dL on statins

Step 3: Monitoring and Titration

Initial follow-up at 6-12 weeks 2:

• Fasting lipid panel
• Liver function tests
• Creatinine
• Glucose/HbA1c
• Assess medication adherence and lifestyle modifications

Titrate therapy to achieve:

• LDL-C <100 mg/dL (or <70 mg/dL if very high risk)
• Non-HDL-C <130 mg/dL (or <100 mg/dL if very high risk) 1, 3, 7
• Triglycerides <150 mg/dL ideally 2

Critical Pitfalls to Avoid

1. Do not delay statin therapy while attempting lifestyle modifications alone—this patient's HDL is critically low and requires immediate pharmacologic intervention 4, 6

2. Do not use gemfibrozil with statins—use fenofibrate if fibrate therapy needed to reduce myopathy risk 8

3. Do not ignore alcohol consumption—this is often the most correctable cause of this lipid pattern 12, 13

4. Do not use bile acid sequestrants when triglycerides >200 mg/dL—they can worsen hypertriglyceridemia 7

5. Do not target HDL-C pharmacologically as primary goal—focus on LDL-C and non-HDL-C reduction; HDL improvement is secondary 14, 9

6. Do not overlook diabetes screening—this lipid pattern is highly associated with metabolic syndrome and diabetes 5, 14

Special Considerations

If triglycerides were ≥500 mg/dL: Fibrate or niacin would be indicated before statin therapy to prevent pancreatitis 1, 3, 7

If patient has established ASCVD: More aggressive LDL-C target (<70 mg/dL) and non-HDL-C target (<100 mg/dL) are reasonable 1, 3

If patient has diabetes: Automatically qualifies for high-intensity statin therapy and more aggressive targets 5, 6